Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Spravato nasal spray is administered by the patient under the supervision of a health care provider ... For too long, health ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a boon to scores of severely depressed patients in Singapore. Since October 2020 ...

PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

The agencies were also aligned on ARS Pharmaceuticals adrenaline-based nasal spray for anaphylaxis treatment. Marketed as neffy in the US and Eurneffy in Europe, the drug became the first needle-free ...

"The clock is ticking for the virus to evolve to more easily infect and potentially transmit from human to human, which would be a concern," said Texas Biomed Professor Luis Martinez-Sobrido ...

Credit: PattyPhoto/Shutterstock. Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284, for the treatment of cancer cachexia.

PH284 is an investigational pherine nasal spray differentiated from all current treatments for the loss of appetite associated with chronic disorders, such as cancer. In the study, PH284 ...